Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (Tables)

v3.21.1
Quarterly Financial Information (Tables)
3 Months Ended
Sep. 30, 2020
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Balance Sheet
    
As of September 30, 2020
 
    
As Previously
Reported
    
Restatement
Adjustment
    
As Restated
 
Unaudited Condensed Balance Sheet
                          
Total assets
   $ 693,957,206      $ —        $ 693,957,206  
    
 
 
    
 
 
    
 
 
 
Liabilities and shareholders’ equity
                          
Total current liabilities
   $ 1,052,132      $ —        $ 1,052,132  
Deferred legal fees
     239,161                    
Deferred underwriting commissions
     24,150,000        —          24,150,000  
Derivative warrant liabilities
     —          56,334,070        56,334,070  
    
 
 
    
 
 
    
 
 
 
Total liabilities
     25,441,293        56,334,070        81,536,202  
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption
     663,276,660        (56,334,070      606,942,590  
Shareholders’ equity

                          
Preference shares -
 $0.0001 par value
     —          —          —    
Class A ordinary shares -
 
$0.0001 par value
     267        564        831  
Class B ordinary shares -
 
$0.0001 par value
     1,725        —          1,725  
Additional paid-in-capital
     5,204,860        19,364,816        24,569,676  
Accumulated deficit
     (206,850      (19,365,380      (19,572,230
    
 
 
    
 
 
    
 
 
 
Total shareholders’ equity
     5,000,002        —          5,000,002  
    
 
 
    
 
 
    
 
 
 
Total liabilities and shareholders’ equity
   $ 693,717,955      $ —        $ 693,478,794  
    
 
 
    
 
 
    
 
 
 
Schedule Of Income Statement
 
    
Period From July 3, 2020 (Inception) Through September 30, 2020
 
    
As Previously
Reported
    
Restatement
Adjustment
    
As Restated
 
Unaudited Condensed Statement of Operations
                          
Loss from operations
   $ (164,056    $ —        $ (164,056
Other (expense) income:
                          
Change in fair value of warrant liabilities
     —          (18,076,180      (18,076,180
Financing cost
     —          (1,289,200      (1,289,200
Unrealized loss on investments held in Trust Account
     (42,794      —          (42,794
    
 
 
    
 
 
    
 
 
 
Total other (expense) income
     (42,794      (19,365,380      (19,408,174
    
 
 
    
 
 
    
 
 
 
Net loss
   $ (206,850    $ (19,365,380    $ (19,572,230
    
 
 
    
 
 
    
 
 
 
Basic and Diluted weighted-average Class A common shares outstanding
     69,000,000        —          69,000,000  
    
 
 
    
 
 
    
 
 
 
Basic and Diluted net loss per Class A share
   $ (0.00      —        $ (0.00
    
 
 
    
 
 
    
 
 
 
Basic and Diluted weighted-average Class B common shares outstanding
     17,250,000        —          17,250,000  
    
 
 
    
 
 
    
 
 
 
Basic and Diluted net loss per Class B share
   $ —          —        $ (1.13
    
 
 
    
 
 
    
 
 
 
Schedule Of Cash flows
 
    
Period From July 3, 2020 (Inception) Through September 30, 2020
 
    
As Previously
Reported
    
Restatement
Adjustment
    
As Restated
 
Unaudited Condensed Statement of Cash Flows
                          
Net loss
   $ (206,850    $ (19,365,380    $ (19,572,230
Adjustment to reconcile net loss to net cash used in operating activities
     67,794        19,365,380        19,433,174  
Net cash used in operating activities
     (515,550      —          (515,550
Net cash used in investing activities
     (690,000,000      —          (690,000,000
Net cash provided by financing activities
     693,295,138        —          693,295,138  
    
 
 
    
 
 
    
 
 
 
Net change in cash
   $ 2,779,588      $ —        $ 2,779,588